What is ACAD stock price today?

ACAD (Acadia Pharmaceuticals Inc) stock is trading at $22.16 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is ACAD stock going up or down today?

ACAD stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy ACAD stock now?

The decision to buy ACAD depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is ACAD a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for ACAD based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is ACAD stock overvalued or undervalued?

ACAD currently trades at a P/E ratio of 10.14, which may suggest attractive valuation. Our DCF calculator provides intrinsic value estimates to help determine if ACAD is fairly priced.

What is ACAD's P/E ratio?

ACAD has a price-to-earnings (P/E) ratio of 10.14, which measures how much investors are willing to pay per dollar of earnings. Compare this to industry peers and historical averages for context.

What is ACAD's market cap?

ACAD (Acadia Pharmaceuticals Inc) has a market capitalization of $3.82 billion, making it a small-cap stock.

What is ACAD's price to book ratio?

ACAD trades at a price-to-book (P/B) ratio of 3.11, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does ACAD pay dividends?

ACAD does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is ACAD's dividend yield?

ACAD does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is ACAD stock a good long-term investment?

ACAD's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is ACAD's revenue growth rate?

ACAD has shown revenue growth of 0.1% over recent periods. Consistent revenue growth is a key indicator of business health and competitive positioning.

Yes, ACAD is profitable with a profit margin of 0.4%. This indicates the company generates 0.4 cents of profit for every dollar of revenue.

What are the risks of investing in ACAD?

Key risks for ACAD include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does ACAD compare to its competitors?

Compare ACAD to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize ACAD's performance and positioning.

What is ACAD's stock price target for 2026?

Our AI model provides price targets for ACAD based on fundamental analysis: Bull case $28.81 (+30%), Base case $25.48 (+15%), Bear case $19.94 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about ACAD?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for ACAD. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is ACAD's next earnings report?

ACAD reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

ACAD - Acadia Pharmaceuticals Inc

NYSE * Health Care * Biotechnology

$22.16

$-0.24 (-1.07%)

About Acadia Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. It also develops remlifanserin, which is in phase 2 clinical trial for the treatment of alzheimer's disease psychosis and lewy body dementia psychosis; ACP-211, which is in phase 2 clinical trial to treat major depressive disorder; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; and ACP-271, a GPR88 agonist for the treatment of tardive dyskinesia and huntington's disease and is in phase I trial. In addition, the company develops ACP-2591, a cGP analogue which is in Phase 1 clinical trial to treat rett syndrome and fragile X syndrome; and STOKE Antisense Oligonucleotide Program, which is in discovery program for SYNGAP1 syndrome. It has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop, and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

ACAD Key Statistics

Market Cap

$3.82B

P/E Ratio

10.14

P/B Ratio

3.11

EPS

$2.21

Revenue Growth

+0.1%

Profit Margin

0.4%

Employees

796

How ACAD Compares to Peers

ACAD has the lowest P/E ratio in Biotechnology, suggesting it may be the most undervalued

ACAD has the highest profit margins in Biotechnology

ACAD ranks 2nd in revenue growth vs peers

P/E Rank

of 6

Margin Rank

of 6

Growth Rank

of 6

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
ACAD(This stock)	$3.82B	10.1	0%	0.4%	-
AMGNAmgen Inc	$199.20B	25.8	0%	0.2%	vs AMGN
GILDGilead Sciences	$180.18B	21.4	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$117.05B	30.1	0%	0.3%	vs VRTX
REGNRegeneron Pharmaceuticals	$80.87B	18.4	0%	0.3%	vs REGN
BIIBBiogen Inc	$27.13B	21.4	-0%	0.1%	vs BIIB

Acadia Pharmaceuticals Inc Company Information

Headquarters: California; U.S.A
Website: www.acadia.com
Sector: Health Care
Industry: Biotechnology

ACAD - Acadia Pharmaceuticals Inc

About Acadia Pharmaceuticals Inc

ACAD Key Statistics

How ACAD Compares to Peers

Acadia Pharmaceuticals Inc Company Information

ACAD Lician Score

ACAD Financial Snowflake

Upcoming Events for ACAD